Citations

Showing 10 of 108094 citations.

Glycemic Control and Bone Turnover in Older Mexican Americans with Type 2 Diabetes
Rianon, Nahid , Smith, Scott M. , Lee, MinJae , Pervin, Hannah, Musgrave, Paul W., Watt, Gordon P. , Nader, Shahla, McCormick, Joseph B. , Fisher‐Hoch, Susan P. , Rianon, Nahid J , Khosla, Sundeep , Ambrose, Catherine Glauber

Mayo Clinic

Journal of Osteoporosis | May 13, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-7

10.1155/2018/7153021 | PMID 29862008 Get It

Altered bone quality, caused by underlying metabolic changes of type 2 diabetes (T2D), has been hypothesized to cause altered bone strength and turnover leading to increased fracture risk in T2D patients. Current understanding about changes in bone turnover markers in T2D patients is mainly based on studies focused on Caucasian men and women. However, Hispanic populations have the highest prevalence of both T2D and osteoporosis in the US. We investigated associations of glycemic control (in terms of glycated hemoglobin [HbA1c]) and bone turnover rate in 69 older (≥50 years) Mexican American Cameron County Hispanic Cohort (CCHC) participants with T2D. Multivariable analyses were conducted to assess the associations between HbA1c (%), serum osteocalcin (OC), and serum sclerostin. In agreement with published reports from other racial/ethnic populations, our study found that lower bone turnover (indicated by lower serum OC) occurred in Mexican American men with T2D who had poorer glycemic control. For the women in our study, we found no significant association between glycemic control and OC. In contrast, HbA1c was positively associated with sclerostin for women, with near significance (p=0.07), while no association was found in men. We recommend screening Mexican American individuals with T2D, specifically those with poor glycemic control, for bone loss and fracture risk.
Impact of a History of Hypertension in Pregnancy on Later Diagnosis of Atrial Fibrillation
Kattah, Andrea G. , Weissgerber, Tracey L. , Agarwal, Sanket , Weaver, Amy L. , Vaughan, Lisa E. , Zimmerman, K , Miller, Virginia M. , Zimmerman, Katherine, White, Wendy M, Garovic, Vesna D. , Weissgerber, Tracey L , Scantlebury, Dawn C. , Mielke, Michelle M. , Henkin, Stanislav , White, Wendy , Hayes, Sharonne N.

Mayo Clinic

Journal of the American Heart Association | May 13, 2018 | Volume: 7 | Issue: 10 | Pages: No page available

10.1161/jaha.117.007584 | PMID 29755033 Get It

Background Atrial fibrillation/flutter ( AF ) produces significant morbidity in women and is typically attributed to cardiac remodeling from multiple causes, particularly hypertension. Hypertensive pregnancy disorders ( HPD s) are associated with future hypertension and adverse cardiac remodeling. We evaluated whether women with AF were more likely to have experienced a HPD compared with those without. Methods and Results A nested case–control study was conducted within a cohort of 7566 women who had a live or stillbirth delivery in Olmsted County, Minnesota between 1976 and 1982. AF cases were matched (1:1) to controls based on date of birth, age at first pregnancy, and parity. AF and pregnancy history were confirmed by chart review. We identified 105 AF cases: mean age 57±8 (mean± SD ) years, (controls 56±8 years), 32±8 years (controls 31±8 years) after the first pregnancy. Cases were more likely to have obesity during childbearing years, and hypertension, diabetes mellitus, dyslipidemia, coronary disease, valvular disease, and heart failure at the time of AF diagnosis. Cases were more likely to have a history of HPD s, compared with controls: 28/105 (26.7%) cases versus 12/105 (11.4%) controls, odds ratio: 2.60 (95% confidence interval, 1.21–6.04). After adjustment for hypertension and obesity, the association was attenuated and no longer statistically significant; odds ratio (95% confidence interval, 2.12 (0.92–5.23). Conclusions Women with AF are more likely to have had a HPD , a relationship at least partially mediated by associated obesity and hypertension. Given the high morbidity of AF , studies evaluating the benefit of screening for and management of cardiovascular risk factors in women with a history of HPD should be performed.
Technical Note: Using dual step wedge and 2D scintillator to achieve highly precise and robust proton range quality assurance
Robertson, Daniel , Keole, Sameer R., Shen, Jiajian , Robertson, Daniel G, Bues, Martin , Shen, Jiajian , Deng, Wei , Liu, Wei , Sio, Terence T.

Mayo Clinic

Medical Physics | May 13, 2018 | Volume: 45 | Issue: 7 | Pages: 2947-2951

10.1002/mp.12951 | PMID 29754455 Get It

PurposeThe purpose of this study was to develop a fast method for proton range quality assurance (QA) using a dual step wedge and two‐dimensional (2D) scintillator and to evaluate the robustness, sensitivity, and long‐term reproducibility of this method.MethodsAn in‐house customized dual step wedge and a 2D scintillator were developed to measure proton ranges. Proton beams with homogenous fluence were delivered through wedge, and the images captured by the scintillator were used to calculate the proton ranges by a simple trigonometric method. The range measurements of 97 energies, comprising all clinically available synchrotron energies at our facility (ranges varying from 4 to 32 cm) were repeated ten times in all four gantry rooms for range baseline values. They were then used for evaluating room‐to‐room range consistencies. The robustness to setup uncertainty was evaluated by measuring ranges with ±2 mm setup deviations in the x, y, and z directions. The long‐term reproducibility was evaluated by 1 month of daily range measurements by this method.ResultsRanges of all 97 energies were measured in less than 10 minutes including setup time. The reproducibility in a single day and daily over 1 month is within 0.1 and 0.15 mm, respectively. The method was very robust to setup uncertainty, with measured range consistencies within 0.15 mm for ±2 mm couch shifts. The method was also sensitive enough for validating range consistencies among gantry rooms and for detecting small range variations.ConclusionsThe new method of using a dual step wedge and scintillator for proton range QA was efficient, highly reproducible, and robust. This method of proton range QA was highly feasible and appealing from a workflow point of view.
Significance of an Increase in Diastolic Blood Pressure During a Stress Test in Terms of Comorbidities and Long-Term Total and CV Mortality
Sydó, Tibor, Carta, Karina Auristela Gonzalez, Hussain, Nasir , Murphy, Joseph G. , Squires, Ray W. , Allison, Thomas G. , Sydó, Nóra, Gonzalez Carta, Karina A, Sydó, Nóra , Merkely, Béla , López-Jiménez, Francisco

Mayo Clinic

American Journal of Hypertension | May 12, 2018 | Volume: 31 | Issue: 9 | Pages: 976-980

10.1093/ajh/hpy080 | PMID 29767671 Get It

Abstract BACKGROUND A decrease in diastolic blood pressure (DBP) with exercise is considered normal, but the significance of an increase in DBP has not been validated. Our aim was to determine the relationship of DBP increasing on a stress test regarding comorbidities and mortality. METHODS Our database was reviewed from 1993 to 2010 using the first stress test of a patient. Non-Minnesota residence, baseline cardiovascular (CV) disease, rest DBP <60 or >100 mm Hg, and age <30 or ≥80 were exclusion criteria. DBP response was classified: normal if peak DBP–rest DBP < 0, borderline 0–9, and abnormal ≥10 mm Hg. Mortality was determined from Mayo Clinic records and Minnesota Death Index. Logistic regression was used to determine the relationship of DBP response to the presence of comorbidities. Cox regression was used to determine total and CV mortality risk by DBP response. All analyses were adjusted for age, sex, and resting DBP. RESULTS Twenty thousand seven hundred sixty patients were included (51 ± 11 years, female n = 7,314). Rest/peak averaged DBP 82 ± 8/69 ± 15 mm Hg in normal vs. 79 ± 9/82 ± 9 mm Hg in borderline vs. 76 ± 9/92 ± 11 mm Hg in abnormal DBP response. There were 1,582 deaths (8%) with 557 (3%) CV deaths over 12 ± 5 years of follow-up. In patients with borderline and abnormal DBP response, odds ratios for obesity, hypertension, diabetes, and current smoking were significant, while hazard ratios for total and CV death were not significant compared with patients with normal DBP response. CONCLUSIONS DBP response to exercise is significantly associated with important comorbidities at the time of the stress test but does not add to the prognostic yield of stress test.
Midlife vascular risk factors and midlife cognitive status in relation to prevalence of mild cognitive impairment and dementia in later life: The Atherosclerosis Risk in Communities Study
Gottesman, Rebecca F. , Sharrett, A. Richey , Tapia, Amanda L. , DavisThomas, Sonia, Windham, B. Gwen , Coker, Laura H., Albert, Marilyn S. , Mosley, Thomas H., Thomas, Sonia , Gottesman, Rebecca F , Knopman, David S. , Schneider, Andrea L.C. , Alonso, Álvaro , Coresh, Josef , Mosley, Thomas H., Thomas, Sonia M

Mayo Clinic

Alzheimer's & Dementia | May 12, 2018 | Volume: 14 | Issue: 11 | Pages: 1406-1415

10.1016/j.jalz.2018.03.011 | PMID 29763593 Get It

Abstract Introduction The interplay between midlife vascular risk factors and midlife cognitive function with later life mild cognitive impairment (MCI) and dementia (DEM) is not well understood. Methods In the Atherosclerosis Risk in Communities Study, cardiovascular risk factors and cognition were assessed in midlife, ages 45–64 years. In 2011–2013, 20–25 years later, all consenting Atherosclerosis Risk in Communities participants underwent a cognitive and neurological evaluation and were given adjudicated diagnoses of cognitively normal, MCI, or DEM. Results In 5995 participants with complete covariate data, midlife diabetes, hypertension, obesity, and hypercholesterolemia were associated with late‐life MCI and DEM. Low midlife cognition function was also associated with greater likelihood of late‐life MCI or DEM. Both midlife vascular risk factors and midlife cognitive function remained associated with later life MCI or DEM when both were in the model. Discussion Later life MCI and DEM were independently associated with midlife vascular risk factors and midlife cognition.
Parenteral Nutrition in Interventional Radiology: Consideration and Management of the Patient
Kapoor, Baljendra , Wang, Weiping , Moon, Eunice

Mayo Clinic

Digestive Disease Interventions | May 11, 2018 | Volume: 02 | Issue: 01 | Pages: 079-084

10.1055/s-0038-1651484 Get It

AbstractThe approach for patients on parenteral nutrition is typically multidisciplinary. Catheters for parenteral nutrition are primarily placed by interventional radiologists under image guidance. Therefore, adequate knowledge of different catheters, including their indications and complications, as well as management of the complications is exceptionally important for interventional radiologists as well as the referring service. In this review, we discuss different aspects of parenteral nutrition, including infectious complications and the strategy for their prevention and management.
When flawed modeling justifies cost‐effectiveness: Making sense of “Band‐Aid” modeling
Borah, Bijan J. , John, Denny , Moriarty, James P. , Borah, Bijan J

Mayo Clinic

Cancer | May 11, 2018 | Volume: 124 | Issue: 15 | Pages: 3266-3267

10.1002/cncr.31545 | PMID 29750832 Get It

See reply on pages 3267‐70, this issue
Comparative Characterization of Osteoclasts Derived From Murine Bone Marrow Macrophages and RAW 264.7 Cells Using Quantitative Proteomics
Ng, Andrew YH, Shen, Shichen, Oursler, Merry Jo, Qu, Jun , Oursler, Merry J, Ng, Andrew YH, Tu, Chengjian , Xu, Ding , Yang, Shuying

Mayo Clinic

JBMR Plus | May 11, 2018 | Volume: 2 | Issue: 6 | Pages: 328-340

10.1002/jbm4.10058 | PMID 30460336 Get It

ABSTRACT Osteoclasts are bone‐resorbing cells differentiated from macrophage/monocyte precursors in response to macrophage colony‐stimulating factor (M‐CSF) and receptor activator of NF‐κB ligand (RANKL). In vitro models are principally based on primary bone marrow macrophages (BMMs), but RAW 264.7 cells are frequently used because they are widely available, easy to culture, and more amenable to genetic manipulation than primary cells. Increasing evidence, however, has shown that the vastly different origins of these two cell types may have important effects on cell behavior. In particular, M‐CSF is a prerequisite for the differentiation of BMMs, by promoting survival and proliferation and priming the cells for RANKL induction. RAW 264.7 cells readily form osteoclasts in the presence of RANKL, but M‐CSF is not required. Based on these key differences, we sought to understand their functional implications and how it might affect osteoclast differentiation and related signaling pathways. Using a robust and high‐throughput proteomics strategy, we quantified the global protein changes in osteoclasts derived from BMMs and RAW 264.7 cells at 1, 3, and 5 days of differentiation. Data are available via ProteomeXchange with the identifier PXD009610. Correlation analysis of the proteomes demonstrated low concordance between the two cell types ( R 2 ≈ 0.13). Bioinformatics analysis indicate that RANKL‐dependent signaling was intact in RAW 264.7 cells, but biological processes known to be dependent on M‐CSF were significantly different, including cell cycle control, cytoskeletal organization, and apoptosis. RAW 264.7 cells exhibited constitutive activation of Erk and Akt that was dependent on the activity of Abelson tyrosine kinase, and the timing of Erk and Akt activation was significantly different between BMMs and RAW 264.7 cells. Our findings provide the first evidence for major discrepancies between BMMs and RAW 264.7 cells, indicating that careful consideration is needed when using the RAW 264.7 cell line for studying M‐CSF‐dependent signaling and functions. © 2018 American Society for Bone and Mineral Research. © 2018 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
Faculty Opinions recommendation of Alzheimer's disease susceptibility genes modify the risk of Parkinson disease and Parkinson's disease-associated cognitive impairment.
Caviness, John N.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | May 11, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.733114736.793545510 Get It

Device-Related Thrombus After Left Atrial Appendage Closure
Dukkipati, Srinivas R. , Holmes, David R. , Doshi, Shephal K. , Swarup, Vijendra, Gibson, Douglas , Maini, Brijeshwar , Gordon, Nicole, Main, Michael L., Reddy, Vivek Y. , Reddy, Vivek Y , Kar, Saibal , Maini, Brijeshwar

Mayo Clinic

Circulation | May 11, 2018 | Volume: 138 | Issue: 9 | Pages: 874-885

10.1161/circulationaha.118.035090 | PMID 29752398 Get It

Background: In patients with atrial fibrillation, left atrial appendage closure with the Watchman device prevents thromboembolism from the left atrial appendage; however, thrombus may form on the left atrial face of the device, and then potentially embolize. Herein, we studied the incidence, predictors, and clinical outcome of device-related thrombus (DRT) using a large series of clinical trial cohorts of patients undergoing Watchman implantation. Methods: We studied the device arms of 4 prospective Food and Drug Administration trials: PROTECT-AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) (n=463); PREVAIL (Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) (n=269); CAP (Continued Access to PROTECT AF registry) (n=566); and CAP2 (Continued Access to PREVAIL registry) (n=578). Surveillance transesophageal echocardiographs were performed at 45 days and 12 months in all patients, and also at 6 months in the randomized control trials. We assessed both the incidence of DRT during these transesophageal echocardiographs (and other unscheduled transesophageal echocardiographs), and clinical outcomes of postprocedure stroke or systemic embolism (SSE) and adjusted for CHA 2 DS 2 -VASC and HAS-BLED scores. Results: Of 1739 patients who received an implant (7159 patient-years follow-up; CHA 2 DS 2 -VASc=4.0), DRT was seen in 65 patients (3.74%). The rates of SSE with and without DRT were 7.46 and 1.78 per 100 patient-years (adjusted rate ratio, 3.55; 95% confidence interval [CI], 2.18–5.79; P <0.001), and ischemic SSE rates were 6.28 and 1.65 per 100 patient-years (adjusted rate ratio, 3.22; 95% CI, 1.90–5.45, P <0.001). On multivariable modeling analysis, the predictors of DRT were as follows: history of transient ischemic attack or stroke (odds ratio [OR], 2.31; 95% CI, 1.26–4.25; P =0.007), permanent atrial fibrillation (OR, 2.24; 95% CI, 1.19–4.20; P =0.012); vascular disease (OR, 2.06; 95% CI, 1.08–3.91; P =0.028); left atrial appendage diameter (OR, 1.06 per mm increase; 95% CI, 1.01–1.12; P =0.019); left ventricular ejection fraction (OR, 0.96 per 1% increase; 95% CI, 0.94–0.99; P =0.009). DRT and SSE both occurred in 17 of 65 patients (26.2%). Of the 19 SSE events in these patients with DRT, 9 of 19 (47.4%) and 12 of 19 (63.2%) occurred within 1 and 6 months of DRT detection. Conversely, after left atrial appendage closure, most SSEs (123/142, 86.62%) occurred in patients without DRT. Conclusions: After left atrial appendage closure with Watchman, DRT (≈3.7%) is not frequent but, when present, is associated with a higher rate of stroke and systemic embolism.